Objective: To investigate the effect of weight reduction induced by gastric bypass operation (GBO), on the peripheral resistance to insulin in extremely obese subjects.
Design: A three-stage euglycemic clamp was applied to assess the metabolic clearance rate of glucose (g-MCR) in lean controls and in obese subjects, prior to and 6-12 months post operation.
Subjects: Six obese subjects (four obese normoglycemics-ON and two obese non-insulin dependent diabetics-OD) before and after GBO and six healthy, lean controls (LC) were compared.
Main Outcome Measures: Body mass index after GBO, metabolic clearance rate of glucose under increasing insulin concentrations.
Results: GBO resulted in a significant change in body mass index from a pre-operation value (mean +/- s.d.) of 45.0 +/- 8.5 to 30.4 +/- 5.9 kg m-2 and remained significantly greater than controls (23.3 +/- 2.3 kg m-2). Glucose MCR increased from a mean baseline value of 3.0 +/- 1.6 to 6.7 +/- 3.9 ml kg-1 min-1 at post GBO (P) (P < 0.02). Similar effects were obtained under the two higher insulin concentration.
Conclusions: GBO resulted in a massive reduction in BMI, that still remained above normal controls. This could explain the effect of weight reduction to decrease, but not completely reverse, peripheral resistance to insulin associated with obesity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Efficacy of Siddha Pharmacotherapy for Acrochordon: A Case Report.
Cureus
December 2024
Department of Gunapadam, Maria Siddha Medical College and Hospital, Thiruvattar, IND.
Skin tags, medically known as acrochordons, are harmless growths of the epidermis that commonly develop in areas where the skin folds, such as the neck, armpits, or groin. While usually asymptomatic, these lesions can cause discomfort from rubbing or cosmetic issues. They are more prevalent in middle-aged and older individuals and are often correlated with conditions such as obesity, diabetes, and insulin resistance.
View Article and Find Full Text PDFPioneering Use of Extracorporeal Life Support in Intraoperative Cardiac Arrest in Dubai: A Case Report.
Cureus
December 2024
Department of Anaesthesia and Intensive Care, Latifa Hospital, Dubai Health, Dubai, ARE.
We describe, to our knowledge, the first use in Dubai of extracorporeal life support (ECLS) in a patient who suffered intraoperative cardiac arrest due to presumed cardiac channelopathy. A 40-year-old patient presented for open myomectomy surgery. She had no other medical problems apart from obesity.
View Article and Find Full Text PDFChanges in the critical nutrient content of packaged foods and beverages after the full implementation of the Chilean Food Labelling and Advertising Law: a repeated cross-sectional study.
BMC Med
January 2025
Center of Research in Food Environment and Prevention of Obesity and Non-Communicable Diseases (CIAPEC), Institute of Nutrition and Food Technology (INTA), University of Chile, Santiago, Chile.
Background: Chile's Food Labelling Law was implemented in three phases with increasingly stricter limits. After initial implementation, sugars and sodium decreased in packaged foods, with no significant changes for saturated fats. It is unclear whether full implementation is linked with further reformulation or if producers reversed changes due to consumers' preferences.
View Article and Find Full Text PDFmicrobiota model recapitulates and predicts individualised sensitivity to dietary emulsifier.
Gut
January 2025
Microbiome-Host Interactions, INSERM U1306, CNRS UMR6047, Institut Pasteur, Université Paris Cité, Paris, France
Background: Non-absorbed dietary emulsifiers, including carboxymethylcellulose (CMC), directly disturb intestinal microbiota, thereby promoting chronic intestinal inflammation in mice. A randomised controlled-feeding study (Functional Research on Emulsifiers in Humans, FRESH) found that CMC also detrimentally impacts intestinal microbiota in some, but not all, healthy individuals.
Objectives: This study aimed to establish an approach for predicting an individual's sensitivity to dietary emulsifiers via their baseline microbiota.
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions.
Lancet Diabetes Endocrinol
January 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!